News

Maze Therapeutics Welcomes Hervé Hoppenot as New Board Chairman

Maze Therapeutics Welcomes Hervé Hoppenot as New Board Chairman

Maze Therapeutics Welcomes Hervé Hoppenot as Chairman

Maze Therapeutics, Inc. (Nasdaq: MAZE), a pioneering clinical-stage biopharmaceutical company focused on innovative small molecule precision medicines for patients with kidney and metabolic diseases, has announced a significant leadership change. Hervé Hoppenot has been appointed as the new Chairman of the Board of Directors, taking over from Charles Homcy, M.D., who will remain on the Board.

A Vision for Transformation

Hervé Hoppenot expressed his excitement about taking on this vital role at Maze Therapeutics, particularly at a time ripe with opportunities. With promising first-in-human data for MZE782, an oversubscribed $150 million private placement, and several key clinical milestones on the horizon, including the advancement of MZE829 targeting APOL1-mediated kidney disease, there is a palpable sense of optimism within the company. Hoppenot is poised to drive meaningful progress as the company continues to execute its mission in developing therapies that have the potential to change lives.

Experience and Leadership Skills

With over thirty years of robust experience in therapeutic development and commercial leadership, Hoppenot brings a wealth of knowledge to the Maze Board. His recent tenure as Chief Executive Officer at Incyte Corporation, which spanned from 2014 to 2025, has equipped him with invaluable insights. During his time at Incyte, he played a crucial role in transforming the organization from a single-product entity into a diversified biotech leader, growing revenues from $350 million to over $4 billion.

Recognizing Achievements

Jason Coloma, Ph.D., the chief executive officer of Maze, highlighted Hoppenot's extensive company-building experience, acknowledging the substantial contributions he made at Incyte. Hoppenot's leadership will be critical as Maze progresses towards its upcoming milestones in 2026, including initiating Phase 2 trials for MZE782 in both phenylketonuria (PKU) and chronic kidney disease (CKD), as well as the top-line Phase 2 data readout for MZE829 in APOL1-mediated kidney disease. Hoppenot's expertise is expected to propel the company toward delivering transformational therapies for patients.

Acknowledging Contributions

The transition comes with deep gratitude towards Charles Homcy, one of the company's co-founders. His tenure as Chairman has been pivotal in establishing the scientific foundation and the clinical trajectory of Maze Therapeutics. As Homcy steps back from the chairman role, the company is thrilled he will remain an active member of the Board and the R&D Committee, continuing to lend his expertise during this transition.

Maze Therapeutics' Commitment to Innovation

Maze Therapeutics is dedicated to leveraging the power of human genetics to create novel small molecule precision medicines. Guided by their renowned Compass™ platform, the company focuses on genetically validated targets, integrating variant discovery and functionalization, which enables them to advance small molecule programs exhibiting first- or best-in-class potential. Their leading programs include MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor progressing to Phase 2 trials.

Company Information and Resources

Based in South San Francisco, Maze Therapeutics continues to expand its horizons, aiming to address significant unmet medical needs. For more information, you can visit their official website or follow the company on social media platforms. Contact details for further inquiries include Amy Bachrodt for investor relations, and Amanda Lazaro for media relations, both of whom are readily available to provide insights into the company's latest developments.

Frequently Asked Questions

Who is the new Chairman of Maze Therapeutics?

The new Chairman of Maze Therapeutics is Hervé Hoppenot, who succeeds Charles Homcy.

What is Maze Therapeutics focusing on?

Maze Therapeutics specializes in developing small molecule precision medicines for kidney and metabolic diseases.

What are the significant projects under Maze Therapeutics?

The company is advancing MZE829 for APOL1-mediated kidney disease and MZE782 for PKU and CKD.

Where is Maze Therapeutics located?

Maze Therapeutics is headquartered in South San Francisco.

How can I contact Maze Therapeutics?

For inquiries, you can contact Amy Bachrodt for investor relations at abachrodt@mazetx.com or Amanda Lazaro for media inquiries at Amanda@1ABMedia.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 110

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 97

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 84

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 102

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 151

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 84

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 111

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 95

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 135

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 182

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Siebert Financial Secures $100 Million for Innovation and Growth

Updated Category News Views 177

Siebert Financial Initiates Strategic Funding Initiative Siebert Financial Corp. (NASDAQ: SIEB) has taken a significant step by announcing the effective declaration of its shelf registration statement on Form S-3 by the SEC. This move permits the company to raise an impressive $100 million through a variety of securities offerings. Enhancing Financial Flexibility and...

Continue Reading
BTQ Technologies Launches Léonne: A New Era in Blockchain Security

Updated Category News Views 250

BTQ Technologies Introduces Léonne Framework BTQ Technologies Corp. is making waves in the blockchain industry with the unveiling of Léonne, a groundbreaking consensus framework that integrates trust modeling, network analysis, and quantum-resistant cryptography into a cohesive and modular system. This innovative approach positions Léonne as the first of its kind,...

Continue Reading
Annovis Bio Welcomes Matthew Peterson, Ph.D., to Lead Clinical Trials

Updated Category News Views 231

Matthew Peterson, Ph.D., Joins Annovis Bio as Senior Clinical Scientist Annovis Bio Inc. (NYSE: ANVS) is making headlines with the recent addition of Dr. Matthew Peterson as Senior Clinical Scientist. This strategic appointment comes at a critical juncture for the company, which is dedicated to developing innovative therapies targeting neurodegenerative disorders...

Continue Reading
Ironwood's Strategic Shift: Apraglutide Development Focus

Updated Category News Views 252

Ironwood Pharmaceuticals Outlines Strategic Focus on Apraglutide Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading biotechnology company committed to developing innovative therapies for gastrointestinal and rare diseases, has announced a profound strategic shift towards advancing apraglutide, specifically aimed at treating patients with short bowel syndrome (SBS)...

Continue Reading
Chamberlain Group Elevates Home Security with Innovative Smart Lock

Updated Category News Views 341

Chamberlain Group Unveils the Next Generation of Home Security In a groundbreaking move, Chamberlain Group (CG) has introduced the myQ Secure View 3-in-1 Smart Lock, a device that not only acts as a smart lock but also integrates a doorbell and camera. This innovative product marks a significant shift for the company as it extends its reach from garage door innovations to...

Continue Reading